7210 Wareham Drive, Tampa, FL 33647
April 17, 2025 New research released Thursday morning shows a new, oral GLP-1 pill may be just as beneficial to those with Type 2 diabetes as injectable GLP-1 drugs. Eli Lilly said that in Phase 3 studies of over 550 adults, their oral GLP-1 pill, orforglipron, could reduce hemoglobin A1C levels on average by 1.3-1.6% […]
Eli Lilly’s New Weight Loss Pill Shows Promise Read More »
Feb. 27, 2025 WW reported its Q4 and full year 2024 results today. The company’s Board of Directors named Interim President and CEO Tara Comonte, to a permanent role as President and CEO, effective February 26, 2025. “We are pleased with the momentum in our Clinical business in the Fourth Quarter, reflecting the increasing demand
Weight Watchers Reports Q4 and 2024 Yearly Results Read More »
Feb. 18, 2025 “This past year was a pivotal year for Medifast, as we continued to transform our business to meet the changing nature of a health and wellness market that has been revolutionized by the rising acceptance of GLP-1 medications,” said Dan Chard, Chairman & CEO. Fourth quarter 2024 revenue decreased 37.7% to $119.0
Medifast Reports Q4 and Full Year 2024 Results Read More »
Sept. 27, 2024 WeightWatchers Board member Tara Comonte has been appointed Interim Chief Executive Officer. Ms. Comonte succeeds Sima Sistani, who departs from her role as Chief Executive Officer and as a member of the Board, effective today. “During her tenure, Ms. Sistani led the Company’s transformation to a modern digital health organization and extended
Weight Watchers CEO Departs Abruptly Read More »
Sept. 25, 2024 Lindora Clinics, a regional medical weight loss chain based in California, has recently begun franchising. As such, it has filed a 2024 FDD (Franchise Disclosure Document) that describes the franchise, its investment costs, etc. Lindora is a long-established company in the weight loss market, with a variety of weight loss programs, both
Lindora Clinics Franchise Is Well Diversified Read More »
Sept. 19, 2024 Lindora Clinics, a long-time competitor in the medical weight loss market, has begun selling franchises. The firm has 31 sites, focused on the California market, but plans to expand nationally via franchising. Lindora franchisees’ gross revenue can vary, but the data provided in the brand’s 2024 FDD offers insight into potential earnings,
Lindora Clinics Now Selling Franchises Read More »
August 13, 2024 As reported by Fiercehealthcare.com today in an article… The genetic testing company 23andMe sees an opportunity to get in on the weight loss boom. The company, through its Lemonaid Health business, plans to launch a GLP-1 weight loss telehealth membership by the end of the month, it announced last week along with
23 and me To Enter The Weight Loss Market Read More »
August 1, 2024 In August, Certificates of Analysis on the compounded GLP-1 medications available through Hims & Hers will be accessible to customers, in an effort to introduce a higher level of transparency that helps our customers understand what is in the medications they receive, as well as how to understand the high quality standards
Hims & Hers To Offer Certificates of Analysis for Compounded GLP-1s Read More »
July 11, 2024 An article by Endpoints.com cited a study that found that only about 15% of people who began taking GLP-1 drugs such as Wegovy stuck with them after two years, according to a new analysis by pharmacy benefit manager Prime Therapeutics. Prime, which is owned by a group of Blue Cross Blue Shield
Nearly all patients quit weight loss shots within two years, study finds Read More »
May 2, 2024 Management reported that: “We delivered solid performance in the first quarter with end of period subscribers of 4.0 million, improved retention and engagement in our core business, and continued strong growth in our clinical business with 91 thousand end of period clinical subscribers,” said Sima Sistani, the Company’s CEO. “We continue to
Weight Watchers Reports Q1 Results Read More »